Drug intelligence / Profile preview

Matovit

Development stage: Unknown
Lead developer: PT SOHO Industri Pharmasi
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

Matovit is an oral eye health supplement developed and manufactured by Soho Global Health. It is formulated as a combination of bilberry extract, beta-carotene, retinol (vitamin A), and vitamin E. Matovit is primarily used as a supportive therapy to maintain healthy vision, reduce eye fatigue (asthenopia), and protect ocular tissues from oxidative damage, particularly in individuals at risk of age-related macular degeneration or diabetic retinopathy.

Brand names: MatovitMatovit AXMatovit Fifty

Beyond the preview

Go deeper on Matovit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Matovit.

Explore the full profile